We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Redesigned MabThera for Treatment of ALS

News   May 26, 2017 | Original Story from Ben-Gurion University of the Negev

 
Academic Redesigns FDA-Approved MabThera to Treat ALS

Dr. Rachel Lichtenstein, Ben-Gurion University of the Negev

 
 
Advertisement
 

RELATED ARTICLES

Recreating Nature: Chemists Create Synthetic Version of Natural Anti-Cancer Agent

News

Scripps Research chemists Hans Renata, PhD, and Alexander Adibekian, PhD, have discovered a way to efficiently create a synthetic version of a valuable natural compound called cepafungin I, which has shown promise as an anti-cancer agent.

READ MORE

Deep Learning Algorithm Mines the Genome for Therapeutic Targets

News

A team of researchers have developed an algorithm through machine learning that helps predict sites of DNA methylation – a process that can change the activity of DNA without changing its overall structure – and could identify disease-causing mechanisms that would otherwise be missed by conventional screening methods.

READ MORE

Our Antibodies Are Shaped by Our Gut Microbiome Before We Encounter an Infection

News

Researchers have now shown how our beneficial microbes reprogram the repertoire of white blood B cells that produce antibodies and how this helps counter infection.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cell Science Drug Discovery Neuroscience Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE